grant
Molecular and structural characterization of broadly neutralizing anti-HCV antibodies
Organization JOHNS HOPKINS UNIVERSITYLocation BALTIMORE, UNITED STATESPosted 15 Feb 2023Deadline 31 Jan 2028
NIHUS FederalResearch GrantFY2026AIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAffinityAnimal ModelAnimal Models and Related StudiesAnti-HCV AntibodiesAnti-Hepatitis C Virus AntibodiesAnti-viral AgentsAntibodiesAntibody Binding SitesAntibody ResponseAntigenic DeterminantsAwardB blood cellsB cellB cell receptorB cellsB-Cell Antigen ReceptorB-CellsB-LymphocytesB-cellB-cell receptor repertoire sequencingB-cell receptor sequencingBCR repertoire sequencingBCR seqBCR sequencingBCRseqBindingBinding DeterminantsBlood PlasmaCell IsolationCell SegregationCell SeparationCell Separation TechnologyChronicClinical Treatment MoabComplexCountryCryo-electron MicroscopyCryoelectron MicroscopyDevelopmentDiseaseDisease OutcomeDisorderElectron CryomicroscopyEnvelope ProteinEpitopesGeneticGerm LinesGlycoproteinsGoalsHCVHCV AntibodiesHCV IncidenceHCV VaccineHCV infectionHIVHepatitis C AntibodiesHepatitis C IncidenceHepatitis C VaccineHepatitis C Virus AntibodiesHepatitis C virusHepatitis C virus infectionHumanHuman Immunodeficiency VirusesImmune responseImmunologic ModelImmunological ModelsIn VitroIndividualInfectionLAV-HTLV-IIILengthLong-term infectionLymphadenopathy-Associated VirusMeasuresMethodsModern ManMolecularMolecular InteractionMonoclonal AntibodiesParatopesPersonsPhasePlasmaPlasma SerumProcessProteinsPublic HealthReticuloendothelial System, Serum, PlasmaSingle Crystal DiffractionSomatic MutationSortingStructureSurvey InstrumentSurveysT cell responseT-CellsT-LymphocyteTechniquesTimeVaccine AntigenVaccine DesignVaccinesVariantVariationViralViral DiseasesViremiaVirusVirus DiseasesVirus-HIVWorkX Ray CrystallographiesX-Ray CrystallographyX-Ray Diffraction CrystallographyX-Ray/Neutron CrystallographyXray Crystallographyanti-viral compoundanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viralsantibody combining sitecell sortingchronic infectioncryo-EMcryoEMcryogenic electron microscopydesigndesigningdevelop a vaccinedevelop vaccinesdevelopment of a vaccinedevelopmentaleffective therapyeffective treatmentenv Antigensenv Gene Productsenv Glycoproteinsenv Polyproteinsenv Proteinhepatitis C infectionhepatitis C virus incidencehepatitis C virus vaccinehigh definitionhigh-resolutionhost responseimmune system responseimmunoresponseimprovedinfected with HCVinfected with hepatitis Cinfected with hepatitis C virusinfection by hepatitis c virusinfection with HCVinfection with hepatitis Cinfection with hepatitis C virusmAbsmodel of animalmonoclonal Absneutralizing antibodypersistent infectionrational designsomatic variantthymus derived lymphocytevaccine candidatevaccine developmentviraemiaviral infectionviral sepsisvirus envelopevirus infectionvirus-induced diseasevirusemia
Description preview
Summary
More than 70 million people worldwide are infected with hepatitis C virus (HCV), and development of a vaccine
for HCV is essential for disease eradication. Although direct-acting antivirals are highly effective for treatment,
the majority of countries surveyed are not on track to reach the WHO goal of eliminating HCV as a public health…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click